<DOC>
	<DOC>NCT01103323</DOC>
	<brief_summary>This is a randomized, double-blind, placebo-controlled multi-center phase III study to evaluate efficacy and safety of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed on/after all approved drugs for CRC</brief_summary>
	<brief_title>Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy</brief_title>
	<detailed_description>All participants received Best Supportive Care. Acronyms used in Adverse events section: Gastrointestinal (GI), Genitourinary (GU), Not Otherwise Specified (NOS), Absolute Neutrophil Count (ANC), Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Common Terminology Criteria for Adverse Events (CTCAE), International Normalized Ratio (INR), Central nervous system (CNS), Acute respiratory distress syndrome (ARDS), Cranial nerves (CN), Disseminated Intravascular Coagulation (DIC), Cardiac troponin T (cTnT). Abbreviation used in Results section: Data Monitoring Committee (DMC). Adverse event collection will be covered in Adverse events section.</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Histological or cytological documentation of adenocarcinoma of the colon or rectum Progression during or within 3 months following the last administration of approved standard therapies. Patients treated with oxaliplatin in an adjuvant setting should have progressed during or within 6 months of completion of adjuvant therapy Patients with measurable or non measurable disease Eastern Cooperative Oncology Group (ECOG) Performance Status of &lt;/= 1 Life expectancy of at least 3 months Adequate bone marrow, liver and renal function Unstable/uncontrolled cardiac disease History of arterial or venous thrombotic or embolic events Symptomatic metastatic brain or meningeal tumors Patients with evidence or history of bleeding diathesis Interstitial lung disease Persistent proteinuria &gt;/= grade 3 Unresolved toxicity &gt; grade 1 attributed to any prior therapy/procedure excluding alopecia and oxaliplatin induced neurotoxicity &lt;/= Grade 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Metastatic Colorectal Cancer</keyword>
</DOC>